ARCH Venture Partners XII, LLC - Nov 3, 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
10%+ Owner
Signature
ARCH Venture Fund XII, L.P. By: ARCH Venture Partners XII, L.P., its General Partner By: ARCH Venture Partners XII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact
Stock symbol
NMRA
Transactions as of
Nov 3, 2023
Transactions value $
$1,099,945
Form type
4
Date filed
11/7/2023, 06:59 PM
Previous filing
Sep 29, 2023
Next filing
Nov 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NMRA Common Stock Purchase $255K +22.4K +0.58% $11.38 3.88M Nov 3, 2023 By ARCH Venture Fund XII, L.P. F1, F4, F5
transaction NMRA Common Stock Purchase $498K +43.1K +1.11% $11.55 3.93M Nov 6, 2023 By ARCH Venture Fund XII, L.P. F2, F4, F5
transaction NMRA Common Stock Purchase $347K +30.2K +0.77% $11.50 3.96M Nov 7, 2023 By ARCH Venture Fund XII, L.P. F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.08 to $11.82, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.99, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.67, inclusive.
F4 Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F5 As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023.

Remarks:

This Form 4 is filed jointly by ARCH XII, AVP XII LP, AVP XII LLC, Robert Nelsen, Steven Gillis, Keith Crandell (collectively, the "Reporting Persons"). Kristina Burow has direct ownership of common stock and is filing her own Form 4 separately.